Jozef Vermylen
About
In The Last Decade
Jozef Vermylen
88 papers receiving 1.1k citations
Peers
Comparison fields: 5 of 117
- Health, Toxicology and Mutagenesis 465
- Hematology 180
- Pulmonary and Respiratory Medicine 177
- Pollution 171
- Materials Chemistry 161
Countries citing papers authored by Jozef Vermylen
This map shows the geographic impact of Jozef Vermylen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jozef Vermylen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jozef Vermylen more than expected).
Fields of papers citing papers by Jozef Vermylen
This network shows the impact of papers produced by Jozef Vermylen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jozef Vermylen. The network helps show where Jozef Vermylen may publish in the future.
Co-authorship network of co-authors of Jozef Vermylen
This figure shows the co-authorship network connecting the top 25 collaborators of Jozef Vermylen. A scholar is included among the top collaborators of Jozef Vermylen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jozef Vermylen. Jozef Vermylen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | A patient with mild hemophilia A and a high titer antifactor VIII antibody against exogenous factor VIII only: clinical features, surgical management, and partial characterization of the inhibitor | 3 |
| 2 | Direct quantitation of oxidized low-density-lipoprotein (oxldl) and assessment of its pole in atherothrombosis in end-stage renal-disease (esrd) patients | 8 |
| 3 | The antithrombotic effects of calin, a platelet-adhesion inhibitor from the medicinal leech, in a hamster femoral vein platelet-rich mural thrombosis model | 1 |
| 4 | Pai-1 is not synthesized in human platelets | 4 |
| 5 | Disturbed platelet-aggregation to collagen associated with an antibody against a 85-90 kda platelet glycoprotein in a patient with prolonged bleeding-time | 4 |
| 6 | A murine monoclonal-antibody against vonwillebrand-factor (vwf) increases vwf binding to human platelet glycoprotein (gp) ib and gp iib/iiia | 2 |
| 7 | A murine monoclonal-antibody against platelet glycoprotein iib iiia potently inhibits platelet functioning invitro and invivo | 2 |
| 8 | Possible role of platelet activation in the pathogenesis of the transient neonatal hyperammonemia syndrome | 8 |
| 9 | R68070, a combined thromboxane synthase (tsi) and receptor blocker (tra), reduces thrombus formation in rats | 3 |
| 10 | Synergistic effect of udcg212, a phosphodiesterase inhibitor (pde-i), and r68070, a combined thromboxane receptor antagonist (tra) and thromboxane synthase inhibitor (tsi), on platelet camp levels | 2 |
| 11 | Thromboembolic complications and hemostatic changes in cyclosporin-treated cadaveric kidney allograft recipients | 4 |
| 12 | Clinical ineffectiveness of intra-arterial or intra-venous infusions of epoprostenol in patients with peripheral obliterative disease, Stage III to IV | 4 |
| 13 | The prostacyclin stimulating plasma factor (pspf) protects endothelial-cells from exhaustion | 5 |
| 14 | Blood changes and enhanced thromboxane-b2 and 6-keto prostaglandin production in acute plasmodium-bergei infection in hamsters | 2 |
| 15 | Dipyridamole inhibits platelet-aggregation in whole-blood invitro and exvivo | 2 |
| 16 | Reorientation of cyclic endoperoxide metabolism and efficacy of thromboxane synthetase inhibitors (tsi) | 1 |
| 17 | Manipulation of the local thromboxane and prostacyclin balance invivo by anti-thrombotic compounds | 3 |
| 18 | The feasibility of adequate thrombolytic therapy with streptokinase in peripheral arterial occlusions | 7 |
| 19 | L'influence d'un dérivé du niacin sur le système fibrinolytique de l'homme | 1 |
| 20 | Enhancing the fibrinolytic activity in human blood by occlusion of blood vessels | 9 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.